Global Information
회사소개 | 문의 | 비교리스트

비호지킨림프종 치료 시장(2019-2025년)

Non-Hodgkin lymphoma treatment Market 2019-2025

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949657
페이지 정보 영문
가격
US $ 3,600 ₩ 4,252,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,670,000 Printable PDF (Enterprise License)


비호지킨림프종 치료 시장(2019-2025년) Non-Hodgkin lymphoma treatment Market 2019-2025
발행일 : 2020년 06월 페이지 정보 : 영문

세계의 비호지킨림프종 치료 시장은 예측 기간 중 대폭 성장할 예정입니다. 비호지킨림프종은 백혈구에 기인하며, 신체 면역계의 일부에 영향을 미칩니다. 비호지킨림프종의 치료는 연령, 비호지킨림프종의 유형, 비호지킨림프종의 병기 등 몇개의 요인에 따라 다릅니다. 비호지킨림프종의 유병률 증가와 함께 치료제 업계에서 연구개발 활동의 증가 등의 요인이 비호지킨림프종 치료 시장을 촉진합니다. 2017년 Cancer Research UK에 따르면 매년 약 14,100건의 새로운 비호지킨림프종 증례가 영국에서 등록되고 있습니다.

세계의 비호지킨림프종 치료 시장은 세포 유형과 치료 유형에 기반하여 분류됩니다. 세포형별로 시장은 B세포 림프종과 T세포 림프종으로 분류됩니다. B세포 비호지킨림프종의 치료는 주로 질환의 서브타입과 병기에 기반하여 결정됩니다. 일반적으로 화학요법과 방사선 요법은 B세포 비호지킨림프종의 2개의 주요 치료법입니다. 치료 유형별로 시장은 면역치료, 화학요법, 표적치료, 방사선, 줄기세포 이식으로 세분화되고 있습니다.

지역적으로 세계의 비호지킨림프종 치료 시장 리포트 조사는 북미(미국 및 캐나다), 유럽(영국, 독일, 이탈리아, 스페인, 프랑스 및 기타 유럽), 아시아태평양(중국, 일본, 인도, 기타) 및 기타 지역을 다루고 있습니다. 북미는 예측 기간 중 시장에서 큰 점유율을 차지할 것으로 추정되고 있습니다. 아시아태평양은 예측 기간 중 세계의 비호지킨림프종 치료 시장에서 큰 성장률을 보일 것으로 추정되고 있습니다.

세계의 비호지킨림프종 치료 시장에 대해 조사했으며, 시장의 개요와 세포 유형별, 치료법별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트의 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트의 인사이트와 현재의 시장 동향
  • 규칙과 규제

제3장 경쟁 구도

  • 주요 전략 분석
  • 주요 기업 분석
    • AbbVie Inc.
    • AstraZeneca PLC
    • Seattle Genetics Inc.
    • Teva Pharmaceuticals Industries Ltd.
    • Novartis International AG

제4장 시장 결정요인

  • 동기
  • 억제요인
    • 시장 기회

제5장 시장 세분화

  • 세포 유형별 비호지킨림프종 치료 시장
    • B세포
    • T세포
  • 치료 유형별 비호지킨림프종 치료 시장
    • 화학요법
    • 방사선 치료
    • 기타

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타
  • 기타 지역

제7장 기업 개요

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • Epizyme, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Nordic Nanovector ASA
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Seattle Genetics, Inc.
  • Sorrento Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
KSA 20.08.12

LIST OF TABLES

  • 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
  • 2. GLOBAL B-CELL LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL T-CELL LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
  • 5. GLOBAL CHEMOTHERAPY FOR NON-HODGKIN LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL RADIATION THERAPY FOR NON-HODGKIN LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL OTHER THERAPY FOR NON-HODGKIN LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 9. NORTH AMERICAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 10. NORTH AMERICAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
  • 11. NORTH AMERICAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
  • 12. EUROPEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 13. EUROPEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
  • 14. EUROPEAN NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
  • 15. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 16. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
  • 17. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)
  • 18. REST OF THE WORLD NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY CELL TYPE, 2018-2025 ($ MILLION)
  • 19. REST OF THE WORLD NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH AND ANALYSIS BY THERAPY TYPE, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE BY CELL TYPE, 2018 VS 2025 (%)
  • 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE BY THERAPY TYPE, 2018 VS 2025 (%)
  • 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 4. US NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. UK NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. ROE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF THE WORLD NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)

Global Non-Hodgkin lymphoma treatment Market Size, Share & Trends Analysis Report By Cell Type (B-Cell and T-Cell), By Therapy Type (Chemotherapy, Radiation Therapy, and Others), and Forecast 2019-2025

The global Non-Hodgkin lymphoma treatment market is anticipated to grow significantly during the forecast period. Non-Hodgkin lymphoma originates from the white blood cell and affects the parts of the body's immune system. Treatment of Non-Hodgkin lymphoma depends on the several factors such as age, type of Non-Hodgkin lymphoma, and stage of Non-Hodgkin lymphoma. The factor such as increasing R&D activities in therapeutics drugs industry coupled with the increasing prevalence of Non-Hodgkin lymphoma disease will drive Non-Hodgkin lymphoma treatment market. According to Cancer Research UK in 2017, around 14,100 new non-Hodgkin lymphoma cases are registered every year in the UK.

The global Non-Hodgkin lymphoma treatment market is segmented on the basis of Cell type and therapy type. Based on cell type, the market is bifurcated into B-Cell lymphoma and T-Cell lymphoma. The treatment of B-cell Non-Hodgkin lymphoma is mainly based on the subtype and stage of the disease. In general, chemotherapy and radiation therapy are the two principal forms of treatment for B-cell Non-Hodgkin lymphoma. Based on the therapy type, the market is sub-segmented into immunotherapy, chemotherapy, targeted therapy, radiation, and stem cell transplant.

Geographically, the study of the global Non-Hodgkin lymphoma treatment market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. North America is estimated to contribute a significant share in the market during the forecast period. Asia-Pacific is estimated to exhibit a significant growth rate in the global Non-Hodgkin lymphoma treatment market during the forecast period.

Moreover, the study of the global Non-Hodgkin lymphoma treatment market report covers the analysis of various players operating in the market. Some of the key players covered in the report include AbbVie Inc., AstraZeneca PLC, Novartis International AG, Seattle Genetics, Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Merck & Co., Inc., Bayer AG, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., and others. The market players are considerably contributing to the market growth by adopting various strategies to stay competitive in the market.

Research Methodology

The market study of the Non-Hodgkin lymphoma treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for working in Lymphoma landscape, pharmaceutical companies, drug manufacturers, medical device companies, healthcare industry, research organizations, academic institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis by Cell Type

2. Global Non-Hodgkin Lymphoma Treatment Market Research and Analysis by Therapy Type

The Report Covers:

  • Comprehensive research methodology of the Non-Hodgkin lymphoma treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Non-Hodgkin lymphoma treatment market.
  • Insights about market determinants which are stimulating the Non-Hodgkin lymphoma treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Key Strategy Analysis
  • 3.2. Key Company Analysis
    • 3.2.1. AbbVie Inc.
      • 3.2.1.1. Overview
      • 3.2.1.2. Financial Analysis
      • 3.2.1.3. SWOT Analysis
      • 3.2.1.4. Recent Developments
    • 3.2.2. AstraZeneca PLC
      • 3.2.2.1. Overview
      • 3.2.2.2. Financial Analysis
      • 3.2.2.3. SWOT Analysis
      • 3.2.2.4. Recent Developments
    • 3.2.3. Seattle Genetics Inc.
      • 3.2.3.1. Overview
      • 3.2.3.2. Financial Analysis
      • 3.2.3.3. SWOT Analysis
      • 3.2.3.4. Recent Developments
    • 3.2.4. Teva Pharmaceuticals Industries Ltd.
      • 3.2.4.1. Overview
      • 3.2.4.2. Financial Analysis
      • 3.2.4.3. SWOT Analysis
      • 3.2.4.4. Recent Developments
    • 3.2.5. Novartis International AG
      • 3.2.5.1. Overview
      • 3.2.5.2. Financial Analysis
      • 3.2.5.3. SWOT Analysis
      • 3.2.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
    • 4.1. Opportunities

5. Market Segmentation

  • 5.1. Non-Hodgkin Lymphoma Treatment Market by Cell Type
    • 5.1.1. B-Cell
    • 5.1.2. T-Cell
  • 5.2. Non-Hodgkin Lymphoma Treatment Market by Therapy Type
    • 5.2.1. Chemotherapy
    • 5.2.2. Radiation Therapy
    • 5.2.3. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. US
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Amgen Inc.
  • 7.3. AstraZeneca PLC
  • 7.4. Bayer AG
  • 7.5. Bristol Myers Squibb Co.
  • 7.6. Eli Lilly and Co.
  • 7.7. Epizyme, Inc.
  • 7.8. F. Hoffmann-La Roche Ltd.
  • 7.9. Gilead Sciences, Inc.
  • 7.10. GlaxoSmithKline PLC
  • 7.11. Johnson & Johnson Services Inc.
  • 7.12. Merck & Co., Inc.
  • 7.13. Nordic Nanovector ASA
  • 7.14. Novartis International AG
  • 7.15. Pfizer Inc.
  • 7.16. Sanofi SA
  • 7.17. Seattle Genetics, Inc.
  • 7.18. Sorrento Therapeutics, Inc.
  • 7.19. Spectrum Pharmaceuticals, Inc.
  • 7.20. Takeda Pharmaceutical Co. Ltd.
  • 7.21. Teva Pharmaceutical Industries Ltd.
Back to Top
전화 문의
F A Q